ライフサイエンスコーパス: xanthine oxidoreductase

1 catalytic differences characterizing AOX and xanthine oxidoreductase.

2 d to be dependent on the enzymatic action of xanthine oxidoreductase.

3 hereas in cardiac homogenates, NTG inhibited xanthine oxidoreductase activity and scavenged NADPH oxi

4 increased reactive oxygen species (ROS) from xanthine oxidoreductase activity) and could be suppresse

5 d persistent basal and post-MI elevations in xanthine oxidoreductase activity.

6 Established inhibitors of xanthine oxidoreductases (allopurinol oxypurinol, amflut

7 the NOS pathway is countered by induction of xanthine oxidoreductase, an enzyme capable of producing

8 itions occurring during ischemia, myocardial xanthine oxidoreductase and nitrate levels were determin

9 e is limited NO production from erythrocytic xanthine oxidoreductase and nitric-oxide synthase.

10 Xanthine oxidoreductase and nitrotyrosine levels were re

11 ant presence of the oxidative stress markers xanthine oxidoreductase and nitrotyrosine, findings that

12 ofile depends on endothelial NO synthase and xanthine oxidoreductase -catalyzed reduction of nitrite

13 tion in vivo via the generation, in part, of xanthine oxidoreductase-catalyzed NO production.

14 Xanthine oxidoreductase catalyzes the final two steps of

15 tural analogues of the oxidized sites in the xanthine oxidoreductase enzyme family.

16 Xanthine oxidoreductase from bovine milk can be prepared

17 t E-box and TATA-like elements repress human xanthine oxidoreductase gene (hXOR) expression.

18 The xanthine oxidoreductase gene (XOR) encodes an important

19 Xanthine oxidase (XO), also known as xanthine oxidoreductase, has long been considered an imp

20 xygen species arising from NADH oxidation by xanthine oxidoreductase in ischaemia-reperfusion injury

21 Xanthine oxidoreductase inhibition abolished the differe

22 ect that was attenuated significantly by the xanthine oxidoreductase inhibitor allopurinol.

23 n oxidation with ferricyanide but not by the xanthine oxidoreductase inhibitor allopurinol.

24 endothelial NO synthase or treated with the xanthine oxidoreductase inhibitor allopurinol.

25 Xanthine oxidoreductase is a ubiquitous cytoplasmic prot

26 bioactivation: reduction to nitric oxide by xanthine oxidoreductase, nonenzymatic disproportionation

27 ation is mediated by the enzymatic action of xanthine oxidoreductase, nonenzymatic disproportionation

28 wering uric acid in these mice by inhibiting xanthine oxidoreductase with allopurinol could improve t

29 eductants (ie, ascorbate); (4) inhibition of xanthine oxidoreductase with oxypurinol does not inhibit

30 e initiated to address the basis for the low xanthine oxidoreductase (XOR) activity in humans relativ

31 Butyrophilin 1A1 (BTN1A1) and xanthine oxidoreductase (XOR) are highly expressed in th

32 nd pharmacological studies further implicate xanthine oxidoreductase (XOR) as a source of reactive ox

33 Xanthine oxidoreductase (XOR) generates proinflammatory

34 d secretes milk lipid by this mechanism, and xanthine oxidoreductase (XOR) has long been thought to b

35 ive effects of pharmacological inhibitors of xanthine oxidoreductase (XOR) have implicated XOR in man

36 ctase activity) and could be suppressed with xanthine oxidoreductase (XOR) inhibition (i.e., allopuri

37 Allopurinol, a xanthine oxidoreductase (XOR) inhibitor, abrogated the p

38 As xanthine oxidoreductase (XOR) is 1 of the major sources

39 Xanthine oxidoreductase (XOR) is a 300-kDa homodimer tha

40 Our previous studies suggest that xanthine oxidoreductase (XOR) is an important nitrite re

41 Xanthine oxidoreductase (XOR) is the enzyme responsible

42 Xanthine oxidoreductase (XOR) is the rate-limiting enzym

43 Xanthine oxidoreductase (XOR) modulates milk lipid secre

44 Although inhibitors of xanthine oxidoreductase (XOR) or NOX2 NADPH oxidase caus

45 Xanthine oxidoreductase (XOR), a key enzyme of purine me

46 also was associated with increased levels of xanthine oxidoreductase (XOR), a known nitrite reductase

47 Here, we demonstrate that xanthine oxidoreductase (XOR), a prototypic superoxide O

48 ystemic changes arising from inactivation of xanthine oxidoreductase (XOR), an enzyme that catalyzes

49 Allopurinol, an inhibitor of xanthine oxidoreductase (XOR), blocks the oxidation of x

50 of AMP, and generation of uric acid through xanthine oxidoreductase (XOR).

51 ed hemoglobin, acidic disproportionation, or xanthine oxidoreductase (XOR).

52 re different from the well-studied mammalian xanthine oxidoreductases (XOR) and aldehyde oxidoreducta

53 amma (PPARgamma), and its upstream activator xanthine-oxidoreductase (XOR).